Tools like Claimable and Fight Health Insurance use AI to guide people through the insurance appeals process and generate ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Novo Nordisk filed 14 new lawsuits against compounders claiming to contain semaglutide, the component of its Ozempic and ...

Second-quarter results mask deeper concerns ​Novo Nordisk's Q2 numbers came in broadly as expected, with headline figures meeting most analyst f ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

​The real shock came with Novo's decision to slash its 2025 guidance, cutting revenue growth expectations to 8-14% and profit ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and compelling long-term ...